
Arlene Chan, MD, director, Mount Hospital at Perth, discusses the ExteNET trial, which looked at neratinib as extended adjuvant therapy in patients with early-stage HER2-positive breast cancer.

Your AI-Trained Oncology Knowledge Connection!


Published: September 27th 2015 | Updated: